Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
126.73
-1.13 (-0.88%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Novo Nordisk Unusual Options Activity For July 26
Today 15:01 EDT
Via
Benzinga
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Today 10:30 EDT
Small caps continued to lead, while the Nasdaq broke below key levels.
Via
Investor's Business Daily
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
July 25, 2024
Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category.
Via
The Motley Fool
Novo Nordisk Shares Decline Amid Competitive Pressure
July 25, 2024
Novo Nordisk A/S Common Stock (NYSE: NVO) experienced a notable decline on Thursday. This movement follows a significant announcement from competitor Viking Therapeutics Inc. (NASDAQ:VKTX).
Via
Benzinga
Novo Nordisk's Options Frenzy: What You Need to Know
July 25, 2024
Via
Benzinga
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
July 19, 2024
Via
Benzinga
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
July 25, 2024
Viking Therapeutics Inc (NASDAQ:VKTX) shares are rising Thursday after the biotech company announced plans to advance its experimental weight loss drug to late-stage trials.
Via
Benzinga
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
July 25, 2024
Viking Therapeutics stock rocketed Thursday after the company said it's exploring a monthly dose of its weight-loss drug.
Via
Investor's Business Daily
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
July 25, 2024
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.
Via
InvestorPlace
Beware, Wegovy -- Pfizer Is Working on a Competitor
July 25, 2024
Pfizer wants to maintain its recent run of key approvals.
Via
The Motley Fool
3 Fabulous Growth Stocks to Buy and Hold Forever
July 24, 2024
The bull market in growth stocks is more than just chipmakers if investors will only widen their lens to see the opportunities available.
Via
InvestorPlace
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
July 24, 2024
The NHS has prescribed Wegovy far less often than expected due to a shortage of weight management clinics, highlighting significant challenges in meeting growing demand for the weight-loss drug.
Via
Benzinga
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
July 24, 2024
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management.
Via
Benzinga
3 Stocks to Buy if There Is No Interest Rate Cut This Year
July 24, 2024
Here are three stocks to buy and hold for steady gains if the Federal Reserve decides against an interest rate cut in 2024.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
July 23, 2024
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and...
Via
Benzinga
Britain's Drug Regulator Approves Novo Nordisk's Weight Loss Drug Wegovy To Cut Heart Disease Risk In Obese Patients
July 23, 2024
The U.K. MHRA has approved Novo Nordisk's Wegovy (semaglutide) to prevent cardiovascular issues in overweight and obese adults with existing heart conditions. This new indication highlights Wegovy's...
Via
Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
July 23, 2024
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road.
Via
The Motley Fool
Why Hims & Hers Heath Shares Are Surging Today
July 22, 2024
Hims & Hers Health Inc. (NYSE: HIMS) shares are moving higher on Monday amidst the announcement of Kåre Schultz's appointment to the Board of Directors.
Via
Benzinga
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
July 22, 2024
President Biden's decision to drop out may harm healthcare and create market volatility. Kamala Harris could defend his record and support Medicare for All.
Via
Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
July 22, 2024
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in...
Via
Benzinga
7 Sorry Biotech Stocks Set to Make Investors Sad
July 22, 2024
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.
Via
InvestorPlace
Here's My Top Growth Stock to Buy Right Now
July 20, 2024
Hims & Hers shares have multi-bagger growth potential over the years to come.
Via
The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
July 20, 2024
They're small now, but these stocks could grow much larger.
Via
The Motley Fool
Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
July 19, 2024
Skyrocketing demand for GLP-1 medications for weight loss is causing shortages, impacting type 2 diabetics. While some insurers are limiting off-label use, government agencies have yet to prioritize...
Via
Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
July 19, 2024
The Nasdaq tumbled amid chip woes.
Via
Investor's Business Daily
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
July 19, 2024
Eli Lilly's Tirzepatide approved by China's NMPA for long-term weight management, targeting adults with specific BMI criteria.
Via
Benzinga
7 A-Rated Stock Picks With Huge Upside Potential
July 19, 2024
We could be headed to a volatile end to the year. The best way to protect yourself is to invest in A-rated stocks like these.
Via
InvestorPlace
Is Viking Therapeutics a Millionaire-Maker?
July 19, 2024
This biotech stock fits the profile of a potentially big winner to a T.
Via
The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.
Via
Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
July 18, 2024
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.